These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28491265)

  • 1. Experience with ruxolitinib in the treatment of polycythaemia vera.
    Alimam S; Harrison C
    Ther Adv Hematol; 2017 Apr; 8(4):139-151. PubMed ID: 28491265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
    Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
    Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
    Greenfield G; McPherson S; Mills K; McMullin MF
    J Transl Med; 2018 Dec; 16(1):360. PubMed ID: 30558676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
    Passamonti F; Griesshammer M; Palandri F; Egyed M; Benevolo G; Devos T; Callum J; Vannucchi AM; Sivgin S; Bensasson C; Khan M; Mounedji N; Saydam G
    Lancet Oncol; 2017 Jan; 18(1):88-99. PubMed ID: 27916398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
    Reiter A; Harrison C
    Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of polycythaemia vera: a critical review of current data.
    McMullin MF; Wilkins BS; Harrison CN
    Br J Haematol; 2016 Feb; 172(3):337-49. PubMed ID: 26492433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
    Vaddi K; Verstovsek S; Kiladjian JJ
    Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the diagnosis and treatment of patients with polycythaemia vera.
    Hatalova A; Schwarz J; Gotic M; Penka M; Hrubisko M; Kusec R; Egyed M; Griesshammer M; Podolak-Dawidziak M; Hellmann A; Klymenko S; Niculescu-Mizil E; Petrides PE; Grosicki S; Sever M; Cantoni N; Thiele J; Wolf D; Gisslinger H
    Eur J Haematol; 2018 Jul; ():. PubMed ID: 30058088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ruxolitinib (JAKAVI°) and polycythaemia vera Inconclusive evaluation.
    Prescrire Int; 2016 Oct; 25(175):229-231. PubMed ID: 30645821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
    Passamonti F; Palandri F; Saydam G; Callum J; Devos T; Guglielmelli P; Vannucchi AM; Zor E; Zuurman M; Gilotti G; Zhang Y; Griesshammer M
    Lancet Haematol; 2022 Jul; 9(7):e480-e492. PubMed ID: 35597252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The advantages and risks of ruxolitinib for the treatment of polycythemia vera.
    Colafigli G; Scalzulli E; Pepe S; Di Prima A; Efficace F; Martelli M; Foà R; Breccia M
    Expert Rev Hematol; 2020 Oct; 13(10):1067-1072. PubMed ID: 32873088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
    Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
    Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycythemia Vera (PV): Update on Emerging Treatment Options.
    Benevolo G; Vassallo F; Urbino I; Giai V
    Ther Clin Risk Manag; 2021; 17():209-221. PubMed ID: 33758507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
    Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
    Crodel CC; Jentsch-Ullrich K; Reiser M; Jacobasch L; Sauer A; Tesch H; Ulshöfer T; Wunschel R; Palandri F; Heidel FH
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2693-2705. PubMed ID: 34807311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.